Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HTR4 | Q13639 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | ANPEP | P15144 | 1/20 | 0.43 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 3/20 | 0.41 |
| ▸ | RAD52 | P43351 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11627618 | 0.90 | ACHE (0.46) | MEN1KMT2AL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL8170280 | 0.86 | MEN1 (0.57) | MEN1KMT2AHSD17B10ALDH1A1ACHE | |
| SCHEMBL22281737 | 0.85 | ALDH1A1 (0.53) | MEN1KMT2AHSD17B10L3MBTL1KDM4E | |
| SCHEMBL22890934 | 0.85 | HDAC2 (0.48) | MEN1KMT2AL3MBTL1ALDH1A1ACHE | |
| SCHEMBL2759481 | 0.82 | TDP1 (0.57) | ALDH1A1CYP3A4 | |
| SCHEMBL513795 | 0.81 | MEN1 (0.55) | MEN1KMT2AHSD17B10ALDH1A1ANPEP | |
| SCHEMBL165764 | 0.80 | HSD17B10 (0.61) | MEN1KMT2AHSD17B10L3MBTL1KDM4E | |
| SCHEMBL31301221 | 0.80 | DRD2 (0.55) | MEN1KMT2AHSD17B10ALDH1A1ANPEP | |
| SCHEMBL11455501 | 0.80 | KMT2A (0.47) | MEN1KMT2AHSD17B10L3MBTL1KDM4E | |
| SCHEMBL8572773 | 0.79 | MEN1 (0.56) | MEN1KMT2AHSD17B10L3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | MEN1 492/4885KMT2A 3145/4885HSD17B10 4794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.